Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated T regs-Reference-Cited by-同舟云学术

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated T regs

Published:2017-01-17 Issue:462 Volume:10 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Torrey Heather¹,Butterworth John¹,Mera Toshiyuki¹,Okubo Yoshiaki¹,Wang Limei¹,Baum Danielle¹,Defusco Audrey¹,Plager Sara¹,Warden Sarah¹,Huang Daniel¹,Vanamee Eva¹,Foster Rosemary²,Faustman Denise L.¹

Affiliation:

1. Immunobiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA.

2. Department of Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Vincent Center for Reproductive Biology, Boston, MA 02114, USA.

Abstract

An antibody against TNFR2 may treat ovarian cancer by killing tumor cells while limiting the activity of suppressive immune cells.

Funder

American Autoimmune Related Disease Association

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference50 articles.

1. Antibody therapy of cancer

2. T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis: Figure 1.

3. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity;Shimizu J.;J. Immunol.,1999